Retatrutide Clinics in the United States

What Is Retatrutide?

Retatrutide is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously - making it the most potent weight loss peptide in clinical development. Developed by Eli Lilly, Phase 3 trials showed average weight loss exceeding 24% of body weight over 48 weeks, surpassing tirzepatide.

By adding glucagon agonism to the GIP/GLP-1 dual action of tirzepatide, retatrutide further increases energy expenditure and metabolic rate while suppressing appetite. It also has favorable effects on liver fat (NASH) and cardiovascular risk markers.

As of early 2026, retatrutide is in Phase 3 trials and has not yet received FDA approval, though approval is anticipated in 2026-2027.

Who Considers Retatrutide?

• Adults with significant obesity seeking the most effective available weight loss options
• People who have not achieved adequate results on semaglutide or tirzepatide
• Those with metabolic comorbidities (fatty liver, metabolic syndrome) requiring potent intervention
• Early adopters interested in cutting-edge peptide therapy under physician supervision

What to Expect at a Consultation

Consultations for retatrutide follow the same metabolic assessment as other GLP-1 class medications. Given its investigational status, physicians will want to ensure you have a thorough understanding of the current evidence base and any risks associated with using a pre-approval compound.